Navigation Links
YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
Date:6/2/2008

d treatment for prolonged periods was very well tolerated and there was no evidence of rash at any of the three dose levels (100mg, 200mg and 400mg). Although the drug specifically targets the EGF receptor, the minimal side-effects, and particularly the absence of severe cases of rash, cutaneous manifestations and hypomagnesemia continue the prospect of nimotuzumab being therapeutically attractive in this setting.

Investigation of nimotuzumab's survival benefit in a curative patient population ineligible for combined-modality treatment is the subject of a planned late stage trial. In a recent palliative trial in Stage III/IV patients (J Clin. Oncol. 2004 Mar 1;22(5):801-10), the median survival in that patient population was reported to be from 6.8 months to 8.2 months (approximately 28-35 weeks). Furthermore, in an RTOG/ECOG trial in Stage III patients who were candidates for curative treatment (J Natl Cancer Inst 1995 Feb 1;87(3):198-205), standard and hyperfractionated radiation in "good risk" patients resulted in a median overall survival of 11.4 and 12.3 months respectively or approximately 47 to 53 weeks. These results are provided for reference only and readers are cautioned that differences in patient populations with respect to YM's phase I or its proposed phase III with historical RT-alone prevent direct comparisons.

"The data from this trial further supported by as-yet unpublished data from a parallel trial in Korea, continue to confirm that as has been established from clinical trials and commercial sales of nimotuzumab in more than 2,500 patients worldwide, nimotuzumab has a visibly and clinically preferential side-effect profile to the other EGFR targeting molecules currently being marketed," added Mr. Allan.

The poster presented at ASCO was entitled: "Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... -- Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... Biotherapeutics Holdings Corp. (NASDAQ: TLCR ) will issue ... April 27, 2011. Due to the pending merger with Grifols, ... discuss its first quarter results. About Talecris ... Talecris Biotherapeutics is a global biotherapeutic and biotechnology company ...
... 14, 2011 QRxPharma Limited (ASX: QRX ... Patent and Trademark Office (USPTO) issued the Company a ... This patent covers a proprietary dosing algorithm for converting ... IR, thereby more effectively and safely managing acute pain ...
... April 14, 2011 Reportlinker.com announces that ... in its catalogue: Neurology ... – Neurostimulation Devices, Interventional Neurology and Other ... Neurology Devices Market Outlook in China ...
Cached Biology Technology:U.S. Patent and Trademark Office (USPTO) Issues QRxPharma a New Patent for MoxDuo® IR; Extends Patent Coverage to 2029 2U.S. Patent and Trademark Office (USPTO) Issues QRxPharma a New Patent for MoxDuo® IR; Extends Patent Coverage to 2029 3Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 2Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 3Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 4Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 5Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 6Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 7Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 8Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 9Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 10Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 11Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 12Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 13
(Date:7/10/2014)... -- Unisys Corporation,s (NYSE: UIS ) subsidiary in ... that it has been selected by the Dutch Custodial Institutions ... Provision Biometrics solution for penitentiaries across The Netherlands ... a solution based on its open standards-based LEIDA ... is up to seven years, with the new system expected ...
(Date:7/10/2014)... July 3, 2014 Research and Markets ... the "Global Gesture Recognition & Touch-Less Sensing ... to 2020" report to their offering ... Gesture Recognition & Touch-Less Sensing Market to Grow ... a while, but the companies were unable to ...
(Date:7/10/2014)... Intelligence today released forecasts from "The Global National eID ... for National Electronic ID (eID) programs will generate $54 billion ... number of National eID cards in circulation will double from ... with its vast population, will dominate the market representing nearly ... Europe trails a distant second at 11%. ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
... people around the world being sick doesn,t mean making a ... Nyquil. Instead it means turning to the forest to ... aches to chest pains. But while questions persist ... pharmacological cousins, one Harvard researcher is examining the phenomenon from ...
... July 30, 2012 In the years after Columbus, voyage, ... a phenomenon some have attributed to decimation of native populations ... suggests global cooling resulted in fewer fires because both preceded ... [after about A.D. 1500] has been linked previously to the ...
... China A five-country international team, led by Casey ... School of Medicine First Affiliated Hospital identified the NMNAT1 ... one of the most common causes of inherited blindness ... Nature Genetics , reporting the genetic characteristics underlying ...
Cached Biology News:Health care savings, naturally 2Health care savings, naturally 3When the world burned less 2When the world burned less 3When the world burned less 4When the world burned less 5BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis 2
Multidrop Micro high speed 1 l bulk reagent dispenser rapidly, precisely and accurately dispenses microvolumes of 1-50 l into 384- and 96-well microplates....
...
...
Buckets for tube holder inserts...
Biology Products: